CD38 as a targeted therapy (daratumumab) has been approved for multiple myeloma, but it has also been suggested for SADs, particularly SLE, where plasma cells do not express CD20, leading to rituximab resistance; however, they highly express the CD38 (Figure 12A) (45–47). Here, CD38 is linked to systemic lupus erythematosus.